PL355378A1 - Kompozycje polipeptydowe o polepszonej stabilności - Google Patents

Kompozycje polipeptydowe o polepszonej stabilności

Info

Publication number
PL355378A1
PL355378A1 PL00355378A PL35537800A PL355378A1 PL 355378 A1 PL355378 A1 PL 355378A1 PL 00355378 A PL00355378 A PL 00355378A PL 35537800 A PL35537800 A PL 35537800A PL 355378 A1 PL355378 A1 PL 355378A1
Authority
PL
Poland
Prior art keywords
glycerin
compositions
polypeptide
chemical stability
improved stability
Prior art date
Application number
PL00355378A
Other languages
English (en)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Alby David Sharknas
Alex Mark Prokai
Joseph Vincent Rinella Jr
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27341882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL355378(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP37720899A external-priority patent/JP2001181203A/ja
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL355378A1 publication Critical patent/PL355378A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL00355378A 1999-12-16 2000-12-05 Kompozycje polipeptydowe o polepszonej stabilności PL355378A1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17113599P 1999-12-16 1999-12-16
JP37720899A JP2001181203A (ja) 1999-12-16 1999-12-28 安定性が改良されたポリペプチド組成物
US18103000P 2000-02-08 2000-02-08
PCT/US2000/032421 WO2001043762A2 (en) 1999-12-16 2000-12-05 Polypeptide compositions with improved stability

Publications (1)

Publication Number Publication Date
PL355378A1 true PL355378A1 (pl) 2004-04-19

Family

ID=27341882

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355378A PL355378A1 (pl) 1999-12-16 2000-12-05 Kompozycje polipeptydowe o polepszonej stabilności

Country Status (15)

Country Link
EP (1) EP1242121B1 (pl)
JP (1) JP2003523972A (pl)
CN (1) CN1409640A (pl)
AT (1) ATE288765T1 (pl)
AU (1) AU777570B2 (pl)
BR (1) BR0016334A (pl)
CA (1) CA2394213A1 (pl)
DE (2) DE60018105T2 (pl)
DK (1) DK200000375U1 (pl)
EA (1) EA004631B1 (pl)
ES (1) ES2236010T3 (pl)
IL (1) IL150129A0 (pl)
PL (1) PL355378A1 (pl)
PT (1) PT1242121E (pl)
WO (1) WO2001043762A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
JP2006505562A (ja) * 2002-10-17 2006-02-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド 持続放出組成物の放出プロフィールの調節方法
US20050267222A1 (en) * 2002-10-22 2005-12-01 Dainippon Pharmaceutical Co. Ltd. Stabilized composition
BRPI0410972C1 (pt) 2003-06-03 2021-05-25 Novo Nordisk As método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
CA2597815C (en) 2003-11-20 2012-08-28 Solvay (Societe Anonyme) Process for producing an organic compound
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
DK1884507T3 (da) * 2006-07-27 2010-08-16 Cognis Ip Man Gmbh Fremgangsmåde til fremstilling af glycerol
TWI478875B (zh) 2008-01-31 2015-04-01 Solvay 使水性組成物中之有機物質降解之方法
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
FR2935968B1 (fr) 2008-09-12 2010-09-10 Solvay Procede pour la purification de chlorure d'hydrogene
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
EP3202394A1 (de) 2009-07-06 2017-08-09 Sanofi-Aventis Deutschland GmbH Wässrige insulinzubereitungen enthaltend methionin
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
SI2433651T1 (sl) 2010-09-03 2013-06-28 Aug. Hedinger Gmbh & Co. Kg Postopek ugotavljanja aldehidov in ketonov v glicerinu
US9309209B2 (en) 2010-09-30 2016-04-12 Solvay Sa Derivative of epichlorohydrin of natural origin
US9097692B2 (en) 2010-10-01 2015-08-04 Aug. Hedinger Gmbh & Co. Kg Method for quantitatively determining impurities in glycerin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
AU2020398147A1 (en) * 2019-12-06 2022-06-02 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of Type 1 diabetes
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes
EP4602022A1 (en) * 2022-10-13 2025-08-20 Archer Daniels Midland Company Purification of glycerin as excipient in parenteral pharmaceutical applications
IT202300020130A1 (it) 2023-09-29 2025-03-29 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche stabili di amminoacidi, peptidi o proteine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT921812E (pt) * 1996-06-20 2002-04-29 Novo Nordisk As Preparacoes de insulina contendo um halogenuro

Also Published As

Publication number Publication date
DE20021079U1 (de) 2001-03-22
DE60018105T2 (de) 2005-12-29
DE60018105D1 (de) 2005-03-17
ATE288765T1 (de) 2005-02-15
PT1242121E (pt) 2005-05-31
DK200000375U1 (da) 2001-03-16
EA004631B1 (ru) 2004-06-24
AU2049301A (en) 2001-06-25
CN1409640A (zh) 2003-04-09
JP2003523972A (ja) 2003-08-12
ES2236010T3 (es) 2005-07-16
AU777570B2 (en) 2004-10-21
BR0016334A (pt) 2002-09-10
CA2394213A1 (en) 2001-06-21
EA200200684A1 (ru) 2003-02-27
WO2001043762A2 (en) 2001-06-21
WO2001043762A3 (en) 2002-01-10
IL150129A0 (en) 2002-12-01
EP1242121A2 (en) 2002-09-25
EP1242121B1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
IL150129A0 (en) Polypeptide compositions with improved stability
GB0013488D0 (en) Chemical compound
TR200402703T4 (tr) Çözünür CTLA4 mutantları ve bunların kullanımı.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
DE60132498D1 (en) Isoprenoidproduktion
AU2001262345A1 (en) Antigenic composition comprising a polycationic peptide and inosine and cytosine
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
WO2002018572A3 (en) Membrane penetrating peptides and uses thereof
AU2002228650A1 (en) Gas dehydration using membrane and potassium formate solution
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
GB9920908D0 (en) Chalcone coumarins
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
MY124078A (en) Eletriptan hydrobromide monohydrate
MXPA03004539A (es) Luciferasas aisladas y uso de las mismas.
MXPA03004166A (es) Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina.
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
WO2002029104A8 (en) Tumor marker and methods of use
AU7655600A (en) 1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one
AU2002210533A1 (en) Identification of cytotoxic activity from the ink of aplysia punctata
AU2001218083A1 (en) Ace inhibitor-vasopressin antagonist combinations
NZ516605A (en) Novel anti-allergic agents
WO2001070384A3 (de) Verwendung von duftalkoholalkoxylaten als solubilisierhilfsmittel
WO2000000509A3 (en) Peptides for inhibiting hpv e7 proteins
PL357833A1 (pl) Preparaty klejowe
EA200000025A1 (ru) 13-дигидро-3'-азиридиноантрациклины

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)